Compare Verisign, Inc. (VRSN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs Viatris Inc — how do they compare? Verisign, Inc. trades at $287 (market cap $25.94B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| VRSN | VTRS | |
|---|---|---|
Market Cap | $25.94B | $18.95B |
Sector | Technology | Health |
52-Week High | $310.00 | $17.86 |
52-Week Low | $211.49 | $9.49 |
Enterprise Value | $27.25B | $31.07B |
Dividend Yield | 1.13% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal despite strong institutional buying interest. The company maintains exceptional profitability with 49.77% net margins and consistent revenue growth, though recent earnings have been mixed with two misses in the last four quarters. A major antitrust lawsuit filed in September 2026 poses significant regulatory risk, while analyst consensus remains bullish with a $328.50 price target representing 16% upside potential.
The stock presents a compelling value proposition given its strong cash flow generation and dominant market position in domain registry services, but faces headwinds from legal challenges and competitive pressures. Current valuation at 30.64 P/E appears reasonable for the quality of earnings, though the negative shareholder equity position warrants monitoring of debt levels. Upside potential exists if the company successfully navigates regulatory challenges and maintains its pricing power.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
